EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age

Jennifer H Ku iD, Emily Rayens iD, Lina S Sy, Lei Qian, Bradley K Ackerson, Yi Luo, Julia E Tubert, Gina S Lee, Punam P Modha, Yoonyoung Park, Tianyu Sun, Evan J Anderson und 1 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae375 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Jennifer H Ku und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Hospitalization, Vaccine Efficacy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed.

Methods

At Kaiser Permanente Southern California, we conducted a retrospective cohort study to evaluate comparative vaccine effectiveness (cVE) of high-dose (HD), adjuvanted, and standard-dose (SD) cell-based influenza vaccines, relative to the SD egg-based vaccine. We included adults aged ≥65 years who received an influenza vaccine between 1 August 2022 and 31 December 2022, with follow-up up to 20 May 2023. Primary outcomes were: (1) influenza-related medical encounters and (2) polymerase chain reaction (PCR)-confirmed influenza-related hospitalization. Adjusted hazard ratios (aHR) were estimated by Cox proportional hazards regression, adjusting for confounders using inverse probability of treatment weighting (IPTW). cVE (%) was calculated as (1—aHR) × 100 when aHR ≤1, and ([1/aHR]—1) × 100 when aHR >1.

Results

Our study population (n = 495 119) was 54.9% female, 46.3% non-Hispanic White, with a median age of 73 years (interquartile range [IQR] 69–79). Characteristics of all groups were well balanced after IPTW. Adjusted cVEs against influenza-related medical encounters in the HD, adjuvanted, and SD cell-based vaccine groups were 9.1% (95% confidence interval [CI]: .9, 16.7), 16.9% (95% CI: 1.7, 29.8), and −6.3 (95% CI: −18.3, 6.9), respectively. Adjusted cVEs against PCR-confirmed hospitalization in the HD, adjuvanted, and SD cell-based groups were 25.1% (95% CI: .2, 43.8), 61.6% (95% CI: 18.1, 82.0), and 26.4% (95% CI: −18.3, 55.7), respectively.

Conclusions

Compared to the SD egg-based vaccine, HD and adjuvanted vaccines conferred additional protection against influenza-related outcomes in the 2022–2023 season in adults ≥65 years. Our results provide real-world evidence of the comparative effectiveness of currently licensed vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanHospitalizationVaccine EfficacyHumansAgedFemaleMaleRetrospective StudiesAged, 80 and overCaliforniaSeasonsVaccination

Stichwörter der Autor:innen

epidemiologyinfluenzainfluenza vaccineinfluenza-related medical encountersvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Moderna Inc., Cambridge, Massachusetts, USA.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.

ORCID-Profile: Jennifer H Ku, Emily Rayens

Förderung

  • Moderna, Inc

Zitieren

APA

Ku, J. H., Rayens, E., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Tubert, J. E., Lee, G. S., Modha, P. P., Park, Y., Sun, T., Anderson, E. J., & Tseng, H. F. (2024). Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae375

Vancouver

Ku JH, Rayens E, Sy LS, Qian L, Ackerson BK, Luo Y, et al. Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae375

BibTeX
@article{Ku2024,
  author = {Ku, Jennifer H and Rayens, Emily and Sy, Lina S and Qian, Lei and Ackerson, Bradley K and Luo, Yi and Tubert, Julia E and Lee, Gina S and Modha, Punam P and Park, Yoonyoung and Sun, Tianyu and Anderson, Evan J and Tseng, Hung Fu},
  title = {Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae375}
}
Kostenlos starten →